Eli Lilly (LLY) Stock Buyback History
TTM buyback yield 0.64% · Shareholder yield (TTM) 0.64%.
LLY
TTM buyback yield
0.64%
Shareholder yield (TTM)
0.64%
5Y share count change
-6.1%
TTM buyback spend
$5.26B
SBC coverage (TTM)
8.31x
YoY change in spend
+64.3%
5Y CAGR of spend
+52.4%
Peak year (2019)
$4.40B
Cumulative spend
$32.77B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Eli Lilly (LLY) repurchased about $5.26B of stock over the trailing twelve months.
- Diluted share count is down 6.1% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 8.31× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +52.4% per year over the latest 5-year window.
- TTM repurchases used about 66% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $4.11B | $626.00M | $3.48B | 0.90B | -0.7% | 0.43% |
| 2024 | $2.50B | $645.60M | $1.85B | 0.90B | 0.1% | 0.36% |
| 2023 | $750.00M | $628.50M | $121.50M | 0.90B | -4.9% | 0.14% |
| 2022 | $1.50B | $371.10M | $1.13B | 0.95B | -0.4% | 0.43% |
| 2021 | $1.25B | $342.80M | $907.20M | 0.95B | -0.3% | 0.47% |
| 2020 | $500.00M | $308.10M | $191.90M | 0.96B | -0.1% | 0.31% |
| 2019 | $4.40B | $312.40M | $4.09B | 0.96B | -7.4% | 3.50% |
| 2018 | $4.15B | $279.50M | $3.87B | 1.03B | -1.7% | 3.49% |
| 2017 | $299.80M | $281.30M | $18.50M | 1.05B | -4.4% | 0.34% |
| 2016 | $600.10M | $255.30M | $344.80M | 1.10B | -0.4% | 0.74% |
| 2015 | $749.50M | $217.80M | $531.70M | 1.11B | -0.5% | 0.80% |
| 2014 | $800.00M | $156.00M | $644.00M | 1.11B | -0.6% | 1.04% |
| 2013 | $1.70B | $144.90M | $1.55B | 1.12B | -2.6% | 2.98% |
| 2012 | $721.10M | $141.50M | $579.60M | 1.15B | 2.9% | 1.28% |
| 2011 | $0.00 | $147.40M | −$147.40M | 1.11B | 0.7% | — |
| 2010 | $0.00 | $231.00M | −$231.00M | 1.11B | 0.7% | — |
| 2009 | $0.00 | $368.50M | −$368.50M | 1.10B | 0.4% | — |
| 2008 | $0.00 | $255.30M | −$255.30M | 1.09B | 0.3% | — |
| 2007 | $0.00 | $0.00 | $0.00 | 1.09B | 0.4% | — |
| 2006 | $122.10M | $0.00 | $122.10M | 1.09B | -0.6% | 0.22% |
| 2005 | $377.90M | $0.00 | $377.90M | 1.09B | 0.3% | 0.61% |
| 2004 | $0.00 | $0.00 | $0.00 | 1.09B | 0.9% | — |
| 2003 | $281.10M | $0.00 | $281.10M | 1.08B | -0.2% | 0.37% |
| 2002 | $385.20M | $0.00 | $385.20M | 1.08B | -0.6% | 0.56% |
| 2001 | $545.70M | $0.00 | $545.70M | 1.09B | -0.5% | 0.65% |
| 2000 | $1.05B | $0.00 | $1.05B | 1.10B | -0.9% | — |
| 1999 | $1.45B | $0.00 | $1.45B | 1.11B | -1.3% | — |
| 1998 | $2.17B | $0.00 | $2.17B | 1.12B | -0.9% | — |
| 1997 | $351.30M | $0.00 | $351.30M | 1.13B | 1.2% | — |
| 1996 | $314.50M | $0.00 | $314.50M | 1.12B | — | — |
| 1995 | $156.00M | $0.00 | $156.00M | — | — | — |
| 1994 | $111.00M | $0.00 | $111.00M | — | — | — |
| 1993 | $25.80M | $0.00 | $25.80M | — | — | — |
| 1992 | $68.50M | $0.00 | $68.50M | — | — | — |
| 1991 | $69.20M | $0.00 | $69.20M | — | — | — |
| 1990 | $1.07B | $0.00 | $1.07B | — | — | — |
| 1989 | $186.90M | $0.00 | $186.90M | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Eli Lilly (LLY) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Eli Lilly (LLY)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Eli Lilly (LLY)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $4.11B | +64.3% | +$1.61B | ||
| 2024 | $2.50B | +233.3% | +$1.75B | ||
| 2023 | $750.00M | -50.0% | -$750.00M | ||
| 2022 | $1.50B | +20.0% | +$250.00M | ||
| 2021 | $1.25B | +150.0% | +$750.00M | ||
| 2020 | $500.00M | -88.6% | -$3.90B | ||
| 2019 | $4.40B | +6.0% | +$249.30M | ||
| 2018 | $4.15B | +1284.5% | +$3.85B | ||
| 2017 | $299.80M | -50.0% | -$300.30M | ||
| 2016 | $600.10M | -19.9% | -$149.40M | ||
| 2015 | $749.50M | -6.3% | -$50.50M | ||
| 2014 | $800.00M | -52.9% | -$898.10M | ||
| 2013 | $1.70B | +135.5% | +$977.00M | ||
| 2012 | $721.10M | — | +$721.10M | ||
| 2011 | $0 | — | $0 | ||
| 2010 | $0 | — | $0 | ||
| 2009 | $0 | — | $0 | ||
| 2008 | $0 | — | $0 | ||
| 2007 | $0 | -100.0% | -$122.10M | ||
| 2006 | $122.10M | -67.7% | -$255.80M | ||
| 2005 | $377.90M | — | +$377.90M | ||
| 2004 | $0 | -100.0% | -$281.10M | ||
| 2003 | $281.10M | -27.0% | -$104.10M | ||
| 2002 | $385.20M | -29.4% | -$160.50M | ||
| 2001 | $545.70M | -48.2% | -$507.10M | ||
| 2000 | $1.05B | -27.5% | -$400.20M | ||
| 1999 | $1.45B | -33.1% | -$719.60M | ||
| 1998 | $2.17B | +518.4% | +$1.82B | ||
| 1997 | $351.30M | +11.7% | +$36.80M | ||
| 1996 | $314.50M | +101.6% | +$158.50M | ||
| 1995 | $156.00M | +40.5% | +$45.00M | ||
| 1994 | $111.00M | +330.2% | +$85.20M | ||
| 1993 | $25.80M | -62.3% | -$42.70M | ||
| 1992 | $68.50M | -1.0% | -$700,000 | ||
| 1991 | $69.20M | -93.5% | -$998.00M | ||
| 1990 | $1.07B | +471.0% | +$880.30M | ||
| 1989 | $186.90M | — | — |
In 2025, Eli Lilly (LLY) buyback spend totalled $4.11B – surged 64.3% year-over-year.
Across 2020–2025 (5 years), Eli Lilly buyback spend produced a CAGR of +52.4% – sustaining 2 straight years of year-over-year growth.
Eli Lilly buyback spend peaked at $4.40B in 2019; the latest annual figure is $4.11B in 2025 (6.6% below peak).
Across the available history, buyback spend reached its high of $4.40B in 2019 and its low of $0 in 2004.
Within Healthcare, Eli Lilly (LLY) ranks 4th among 8 peers we track. The peer median for buyback spend is $2.19B.
Eli Lilly Buyback Spend 2025: $4.11B
Eli Lilly buyback spend in 2025 was $4.11B, surged 64.3% from 2024.
Eli Lilly Buyback Spend 2024: $2.50B
Eli Lilly buyback spend in 2024 was $2.50B, surged 233.3% from 2023.
Eli Lilly Buyback Spend 2023: $750.00M
Eli Lilly buyback spend in 2023 was $750.00M, plunged 50.0% below 2022.
Eli Lilly Buyback Spend 2022: $1.50B
Eli Lilly buyback spend in 2022 was $1.50B, grew 20.0% from 2021.
Eli Lilly Buyback Spend 2021: $1.25B
Eli Lilly buyback spend in 2021 was $1.25B.
See more financial history for Eli Lilly (LLY).
Sector peers by buyback spend
Companies in the same sector as Eli Lilly, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Thermo Fisher Scientific (TMO) | $3.00B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 8.31×.
Capital allocation mix
How Eli Lilly splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $7.99B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Eli Lilly's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Eli Lilly buy back its own stock?
Yes, Eli Lilly (LLY) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Eli Lilly spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $5.26B (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Eli Lilly's buyback yield?
TTM buyback yield is about 0.64% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Eli Lilly's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.64% combined (TTM-based where available).
Is Eli Lilly diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Eli Lilly's share count changed?
Diluted weighted average shares changed by about -6.1% over roughly five fiscal years (annual income statement data).
What is Eli Lilly's buyback spend?
Latest reported buyback spend for Eli Lilly (LLY) is $5.26B (period ending March 31, 2026).
How has Eli Lilly buyback spend changed year-over-year?
Eli Lilly (LLY) buyback spend changed +64.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Eli Lilly buyback spend?
Eli Lilly (LLY) buyback spend compound annual growth rate is +52.4% over the most recent 5 years available.
When did Eli Lilly buyback spend hit its highest annual value?
Eli Lilly buyback spend reached its highest annual value of $4.40B in 2019.
What was Eli Lilly buyback spend in 2024?
Eli Lilly (LLY) buyback spend in 2024 was $2.50B.
What was Eli Lilly buyback spend in 2025?
Eli Lilly (LLY) buyback spend in 2025 was $4.11B.
Explore more
LLY Overview
Company profile, financial tools, and key metrics
LLY Revenue Counter
Earns $2,291 every second. See per minute, hour, and day.
LLY Earnings Counter
Earns $801.46 per second net profit. See per minute, hour, and day.
LLY Economic Scale
Exceeds Congo, Dem. Rep.'s GDP. Compare with world economies.
LLY What If Invested
What if you had invested $1,000? See historical returns from any date.
LLY How It Makes Money
Discover visual breakdown of $72.25B in revenue — where it comes from and where it goes.
LLY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
LLY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
LLY Daily Price Character
Steady · 48.0% historical win rate (green days). Streaks & record days.
LLY Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.
LLY Dividend Profile
Yield: 0.63%. Safety: 8/8. See full history.
LLY Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
LLY Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
LLY Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
LLY Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.